What is it about?
Due to publication on "The association of use of Pioglitazone and bladder cancer", there is lot of anxiety amongst medical proffessional and pioglitazone present users and ex-users. Our data from 1111 pioglitazone users of varying doses n duration of use didnt reveal a single case of bladder cancer. This is a reassuring data for Indian population. The study is ongoing and subsequent followup data may consolidate our confidance on the molecule.
Featured Image
Why is it important?
Our data has shown that Indian subject doesnt seem to be at the risk of bladder cancer with the cumulative dose consumption of pioglitazone. WE have used NMP22 ,a biomarker for bladder cancer in high risk pioglitazone users, which was not done in any other study. It has certainly built up our confidance on the molecule.
Perspectives
Bladder cancer prevalance in India is low. Most of us are using pioglitazone since many years, but reports on bladder cancer risk amongst pioglitazone users in India is uncommon. Moreover, temporary Government ban on the drug in the past has created more anxiety amongst people with diabetes and medical professionals. This article will help our clinicians for the judicious use of the drug without much fear factor.
Dr Sunil Surajprasad Gupta
Sunil's Diabetes Care n' Research Centre Pvt Ltd
Read the Original
This page is a summary of: Pioglitazone and the risk of bladder cancer: An Indian retrospective cohort study, Indian Journal of Endocrinology and Metabolism, January 2015, Medknow,
DOI: 10.4103/2230-8210.163187.
You can read the full text:
Contributors
The following have contributed to this page
